Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$7.0B
683M shares
52-week range
$7.27 – $15.93
31% from low
Sector
LABORATORY ANALYTICAL INSTRUMENTS
Exchange
NYSE
CS
Borrow rate
0.41%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.86B | $6.04B | $6.39B | $7.39B | $7.51B | $6.97B | $6.78B | $6.55B |
| Cost of revenue | $4.04B | $4.12B | $4.31B | $4.88B | $4.91B | $4.60B | $4.50B | $4.41B |
| Gross profit | $1.82B | $1.92B | $2.08B | $2.50B | $2.60B | $2.36B | $2.28B | $2.14B |
| Gross margin | 31.0% | 31.8% | 32.5% | 33.9% | 34.6% | 33.9% | 33.6% | 32.7% |
| R&D | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | $413.5M | $551.8M | $706.8M | $972.2M | $1.13B | $696.4M | $1.08B | −$246.2M |
| EBITDA | $814.6M | $879.5M | $765.3M | $1.35B | $1.52B | $1.10B | $1.48B | $138.7M |
| Net income | −$86.9M | $37.8M | $116.6M | $572.6M | $686.5M | $321.1M | $711.5M | −$530.2M |
| Net margin | -1.5% | 0.6% | 1.8% | 7.8% | 9.1% | 4.6% | 10.5% | -8.1% |
| EPS (diluted) | -0.72 | -0.84 | 0.09 | 0.85 | 1.01 | 0.47 | 1.04 | -0.78 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $6.5B | $0.79 | $0.78–$0.80 | 9 |
| 2027 | $6.6B | $0.85 | $0.81–$0.89 | 9 |
| 2028 | $6.9B | $0.91 | $0.80–$1.08 | 3 |
| 2029 | $7.1B | $0.98 | $0.98–$1.00 | 1 |
Forward consensus · source: Financial Modeling Prep
Avantor Inc provides products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company operates through two segments: Laboratory Solutions and Bioscience Production. It offers materials & consumables, equipment & instrumentation, and services & specialty procurement. Product groups include Equipment & Instrumentation, Services & Specialty Procurement, Proprietary Materials & Consumables, and Third-Party Materials & Consumables. Materials & consumables include high-purity chemicals and reagents, lab supplies, customized excipients, single-use assemblies, chromatography products, sample preparation kits, and fluid handling solutions. It operates in the Americas, Europe, and AMEA.
www.avantorsciences.comNo one on the platform currently holds AVTR.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-09-30 | 1,651,100 | $20.6M |
| Bridgewater Associatesas of 2026-03-31 | 128,209 | $1.0M |
No one on the platform has traded AVTR yet.
| $6.1B |
| — |
| HSICHenry Schein, Inc. | $83.75 | -0.63% | $9.5B | — |
| MASIMasimo Corporation | $179.95 | +0.00% | $9.4B | — |
Source: Financial Modeling Prep · peers by sector/industry
Trading at 9.5× earnings vs its 36.7× historical median P/E.
Fair value ≈ $38.47 · price $9.98 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
Wall St is expecting 0.19 EPS for $AVTR Q2 [Reporting 07/23 BMO] http://www.estimize.com/intro/avtr?chart=historical&metric_name=eps&utm_co
View on StockTwits ↗$AVTR Listen to the previous earnings conference call. The turnaround is officially in play with the new CEO and the market is anticipating it. We’re heading back to the 20s.
View on StockTwits ↗$AVTR popping off today with a 6 to 7 percent breakout Seeing aggressive call buying at $10 to $11 strikes No news driving this, just pure momentum Ask-side sweeps in the 6/18 $10 calls are big with 700 to 1,500 lots vs 460 open interest That $10 level is the pivot to watch for next week Plus traders are loading up on 7/17 $11 calls Multiple 300 to 1,000 lot buys hint at a push toward $11 by mid-July AVTR's up about 6.8 percent today and about 10.4 percent over 5 days No puts flowing and 11.9 times options momentum
View on StockTwits ↗$AVTR Sold out. Big gains on a small position. Quite happy. Looking to move more cash toward medical devices $BSX, $MDT, etc. GL to all, I might come back!
View on StockTwits ↗$AVTR Taking my 25% and calling it a day. I really like the company and the new board looks setup to sell this - high quality. However, the turnaround is just getting started. Potentially I miss out on a bigger move but will wait to rebuy. Good luck to those long.
View on StockTwits ↗$AVTR It appears I might have nailed a bottom this morning on that starting position. Added a few more after noting the cross and only regret is not putting on more size from the start. Weird how almost nobody here follows this one.
View on StockTwits ↗$AVTR Started this position back up today at 7.43 given the new board sure looks ready for M&A down the road, activist and numbers not looking that bad and in turnaround mode. What I do not like is the 77K in puts at 7 expires tomorrow ($2 million loss) and they just rolled that into the $6 for another big premium. Someone is betting on a big drop so playing it slow and bids in place.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.